Azcuris Co., Ltd.

팝업레이어 알림

팝업레이어 알림이 없습니다.

Pioneering the Future

of Immune Disease Therapeutics

Azcuris was founded by scientists driven by a single conviction: that patients living
with immune-mediated disease deserve a better solution
Pioneering the Future

of Immune Disease Therapeutics

Azcuris was founded by scientists driven by a single conviction: that patients living
with immune-mediated disease deserve a better solution

R&D

Discovering Next-Generation Therapeutics for immune Disease

Azcuris develops first-in-class, small-molecule therapeutics designed to target the initiation of immune disease at its source. Our proprietary protein-protein interaction (PPI) inhibitor discovery platform enables us to selectively disrupt the intracellular signaling interactions that drive chronic inflammation, with an initial focus on atopic dermatitis, asthma, and related allergic and inflammatory conditions.

Precision Small-Molecule Immunotherapeutics

By identifying and blocking the key protein-protein interactions that initiate the immune response, our pipeline is engineered to halt disease progression at its earliest stage, offering patients a differentiated alternative to conventional biologics and steroid-based treatments via oral administration.

Press & Media

Scroll Scroll